Comment on “MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma”

• Sophie Voruz,
• Filipe Martins,
• Anne Cairoli,
• Olaia Naveiras,
• Krisztian Homicsko,
• Edoardo Missiaglia,
• Laurence de Leval,
• Bettina Bisig,
• Olivier Michielin,
• Sabine Blum

Affiliations

Sophie Voruz

Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland

Filipe Martins

Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland

Anne Cairoli

Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland

Olaia Naveiras

Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland

Krisztian Homicsko

Department of Oncology, University Hospital of Lausanne, Switzerland

Edoardo Missiaglia

Institute of Pathology, CHUV, University Hospital of Lausanne, Switzerland

Laurence de Leval

Institute of Pathology, CHUV, University Hospital of Lausanne, Switzerland

Bettina Bisig

Institute of Pathology, CHUV, University Hospital of Lausanne, Switzerland

Olivier Michielin

Department of Oncology, University Hospital of Lausanne, Switzerland

Sabine Blum

Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland